



Innovative Medicines Initiative

[

# Knowledge Management (KM) at IMI: present and future

Ann Martin, IMI JU




efpia

eHealth  
week

# Knowledge Management

---


- There is a general problem in the data intensive sciences with the management of data sources, information and knowledge within and between institutions (public & private), departments, scientific disciplines, collaborative projects.
  - data islands
  - ethical exploitation of data sources / knowledge
  - incompatibility of analysis tools
  - ....
- **IMI aims to address the KM bottlenecks in pharmaceutical research through dedicated KM projects as well as sharing best practises in terms of managing the knowledge generated in each of the the IMI collaborative projects.**



# Present



- All 23 ongoing IMI projects have a KM component:
  - most projects are sharing data and aiming to derive new knowledge from both retrospective and prospective data
  - KM platform solutions shared e.g. transMART (J&J, U-BIOPRED, oncoTRACK)
  - CDISC standards: MOU in progress
  - KM workgroup initiated
- 3 KM projects:
  - DDMORE: improving the environment for modelling and simulation
  - Open PHACTS: open platform for drugs and targets
  - EHR4CR: business model for re-using EHR for clinical research
  - shared tasks



# Future



- future KM projects will have a KM component
- 2 KM call topics (draft):
  - EMIF: European Medical Information Framework of Patient-Level data in support of a wide range of research studies
  - ETIKS: European Translational Information & Knowledge Management Services

THANK YOU

